JP2017515812A - アルツハイマー病（ａｄ）の処置および予防 - Google Patents

アルツハイマー病（ａｄ）の処置および予防 Download PDF

Info

Publication number
JP2017515812A
JP2017515812A JP2016565334A JP2016565334A JP2017515812A JP 2017515812 A JP2017515812 A JP 2017515812A JP 2016565334 A JP2016565334 A JP 2016565334A JP 2016565334 A JP2016565334 A JP 2016565334A JP 2017515812 A JP2017515812 A JP 2017515812A
Authority
JP
Japan
Prior art keywords
aluminum
aluminum salt
oxyhydroxide
patients
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016565334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515812A5 (enExample
Inventor
マルクス・マントラー
アヒム・シュネーベルガー
ヴォルフガング・ツァウナー
アルネ・フォン・ボニン
フランク・マットナー
ヴァルター・シュミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of JP2017515812A publication Critical patent/JP2017515812A/ja
Publication of JP2017515812A5 publication Critical patent/JP2017515812A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016565334A 2014-04-29 2015-04-29 アルツハイマー病（ａｄ）の処置および予防 Pending JP2017515812A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166388.0 2014-04-29
EP14166355.9 2014-04-29
EP14166388 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059341 WO2015165968A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (2)

Publication Number Publication Date
JP2017515812A true JP2017515812A (ja) 2017-06-15
JP2017515812A5 JP2017515812A5 (enExample) 2018-05-31

Family

ID=53039897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565334A Pending JP2017515812A (ja) 2014-04-29 2015-04-29 アルツハイマー病（ａｄ）の処置および予防

Country Status (12)

Country Link
US (3) US11065273B2 (enExample)
EP (2) EP4209222A1 (enExample)
JP (1) JP2017515812A (enExample)
KR (1) KR102506460B1 (enExample)
CN (1) CN106659736A (enExample)
AU (1) AU2015254665A1 (enExample)
CA (1) CA2946931A1 (enExample)
DK (1) DK3137094T3 (enExample)
FI (1) FI3137094T3 (enExample)
PL (1) PL3137094T3 (enExample)
PT (1) PT3137094T (enExample)
WO (1) WO2015165968A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
JP2017518275A (ja) * 2014-04-29 2017-07-06 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102506460B1 (ko) 2014-04-29 2023-03-03 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
JP2002502802A (ja) * 1997-12-02 2002-01-29 ニューララブ リミテッド アミロイド形成疾患の予防および処置
JP2013523682A (ja) * 2010-03-29 2013-06-17 ノバルティス アーゲー ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
JP2017518275A (ja) * 2014-04-29 2017-07-06 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
NZ536064A (en) * 2002-04-19 2008-06-30 Univ Toronto Immunological methods and compositions for the treatment of alzheimer's disease
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
US10383887B2 (en) 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
KR102506460B1 (ko) 2014-04-29 2023-03-03 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
JP2002502802A (ja) * 1997-12-02 2002-01-29 ニューララブ リミテッド アミロイド形成疾患の予防および処置
JP2013523682A (ja) * 2010-03-29 2013-06-17 ノバルティス アーゲー ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
JP2017518275A (ja) * 2014-04-29 2017-07-06 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADV.DRUG DELIV.REV.,1998,32(3),P.155-172, JPN6019038136, ISSN: 0004386120 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
JP2017518275A (ja) * 2014-04-29 2017-07-06 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防

Also Published As

Publication number Publication date
FI3137094T3 (fi) 2023-03-20
KR102506460B1 (ko) 2023-03-03
EP3137094B1 (en) 2022-12-07
EP3137094A1 (en) 2017-03-08
US11857568B2 (en) 2024-01-02
CN106659736A (zh) 2017-05-10
US11065273B2 (en) 2021-07-20
AU2015254665A1 (en) 2016-11-10
PT3137094T (pt) 2023-03-09
DK3137094T3 (da) 2023-02-27
US20220000908A1 (en) 2022-01-06
CA2946931A1 (en) 2015-11-05
WO2015165968A1 (en) 2015-11-05
EP4209222A1 (en) 2023-07-12
US20170049810A1 (en) 2017-02-23
KR20160145821A (ko) 2016-12-20
US20240148782A1 (en) 2024-05-09
PL3137094T3 (pl) 2023-03-13

Similar Documents

Publication Publication Date Title
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
JP6692755B2 (ja) アルツハイマー病（ａｄ）の処置および予防

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201117